CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01723202
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:24.882247+00:00
Published At: 2025-08-24T00:00:00+00:00
Record Updated At: 2025-08-24
Results Posted At: 2025-08-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Follicular Thyroid Cancer", "Insular Thyroid Cancer", "Papillary Thyroid Cancer", "Recurrent Thyroid Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-24"
protocolSection.identificationModule.nctId: "NCT01723202"
protocolSection.identificationModule.officialTitle: "A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-08-24"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.